CAPR: FDA issued a CRL for Deramiocel, citing insufficient evidence of effectiveness
FDA issued a CRL for Capricor Therapeutics' Deramiocel, citing insufficient evidence of effectiveness and clinical deficiencies, despite HOPE-2 and HOPE-3 meeting primary endpoints. The company is reviewing the letter and has funds for at least 12 months of operations, according to the company.
How this was made

The 30-second read
Why it matters
The regulatory denial is a material negative catalyst, likely triggering a sell‑off and increasing volatility.
Market read
The CRL is a fresh, material regulatory event for CAPR, creating immediate trading relevance.
What to watch
Potential for partnership or licensing of Deramiocel data to larger pharma could mitigate downside.
Background
Capricor Therapeutics announced a resubmission of its Deramiocel BLA; the FDA's CRL cites insufficient efficacy despite positive trial endpoints.
Ticker impact
FDA issued a complete response letter rejecting Capricor Therapeutics' resubmitted Deramiocel BLA due to insufficient efficacy evidence.
downward pressure as investors price in the regulatory setback
Regulatory denials for biotech drugs typically trigger sharp sell‑offs; no mitigating data were provided.
Market effects
Biotech sector may see broader risk‑off pressure on other companies awaiting FDA decisions.
U.S. biotech stocks could experience modest declines in Nasdaq‑listed peer group.
Limited to investors focused on U.S. biotech pipelines; minimal global macro effect.
Counterpoint
If Capricor can address FDA concerns quickly, the stock may rebound on a future resubmission.
Key entities
- companyCapricor Therapeutics, Inc.
Biotech firm developing Deramiocel for cardiac repair.
- regulatorU.S. Food and Drug Administration
Issued the complete response letter rejecting the BLA.


